Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 151 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: donepezil (Aricept) Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Donepezil on Smoking

NCT01250977
View directory record Official record
Conditions
Smoking
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

NCT02822573
View directory record Official record
Conditions
Cognitive Dysfunction, Memory Impairment
Interventions
Donepezil 5 mg, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
278
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 206 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 8, 2026, 2:16 AM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 8, 2026, 2:16 AM EDT
Not yet recruiting Phase 2 Interventional

An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa

NCT06518941
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Memory and Mental Health in Aging

NCT02988908
View directory record Official record
Conditions
Memory
Interventions
Donepezil, Placebos
Drug
Lead sponsor
Stanford University
Other
Eligibility
55 Years to 90 Years
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Results available

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

NCT06285240
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1167, Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Hallandale, Florida • Decatur, Georgia • Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 2 Interventional

VI-1121 for the Treatment Alzheimer's Disease

NCT01428362
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VI-1121, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
San Francisco, California • Santa Monica, California • Sunrise, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 2 Interventional

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Rasagiline
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 2 Interventional

An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis

NCT01146509
View directory record Official record
Conditions
Migraine Headache
Interventions
Aricept (donepezil hydrochloride)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chicago, Illinois • Springfield, Missouri • Mount Vernon, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

NCT00948909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, ABT-126, donepezil
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Fresno, California • West Palm Beach, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01527916
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
placebo, donepezil, ABT-126
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Delray Beach, Florida • Tampa, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 8, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional Results available

12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

NCT02586909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RVT-101 35 mg tablets
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 86 Years
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Acetylcholine and Attention on Visual Spatial Representations in the Brain

NCT05003063
View directory record Official record
Conditions
Visual Perception, Attention, Information Processing, Cholinergic System
Interventions
Donepzil, Placebo oral tablet
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 4 Interventional Results available

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

NCT00934375
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Aricept (donepezil hydrochloride), placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
145 participants
Timeline
2006 – 2007
U.S. locations
49
States / cities
Alabaster, Alabama • Peoria, Arizona • Sun City, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 8, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

NCT01712074
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-05212377 (SAM-760), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 8, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

NCT00895895
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
37
States / cities
Phoenix, Arizona • Costa Mesa, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 8, 2026, 2:16 AM EDT
Withdrawn Phase 4 Interventional

Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

NCT00711204
View directory record Official record
Conditions
Severe Alzheimer's Disease
Interventions
Donepezil Hydrochloride (Aricept)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

NCT02006641
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 3 Interventional

Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer

NCT00006349
View directory record Official record
Conditions
Cognitive/Functional Effects, Delirium, Depression, Lung Cancer, Radiation Toxicity
Interventions
vitamin E, donepezil hydrochloride, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
15
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 4 Interventional Results available

Detecting an Early Response to Donepezil With Measures of Visual Attention

NCT03073876
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil Hydrochloride, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years to 95 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 8, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

NCT00754052
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
11 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions

NCT01276067
View directory record Official record
Conditions
Healthy
Interventions
Donepezil
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 8, 2026, 2:16 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Donepezil on Gait and Balance in Parkinson's Disease

NCT01521117
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 8, 2026, 2:16 AM EDT